Jointly sponsored by the American Academy of CME, Inc and Princeton CME

Target Audience

This activity is designed for managed markets physicians, pharmacists, and nurses.

Learning Objectives

After completing this activity, participants should be able to:

• Define the prevalence and clinical and economic burden of chronic idiopathic constipation in the United States
• Outline the criteria for diagnosis of chronic idiopathic constipation
• Summarize the benefits and limitations of traditional methods for the management of chronic idiopathic constipation
• Describe the safety and efficacy of novel treatment options for chronic idiopathic constipation management
• Incorporate novel therapies for chronic idiopathic constipation into clinical decisions

Credit Eligibility

To be eligible for documentation of credit, all participants must participate in the full educational activity, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. Participants who successfully complete the post-test and evaluation form online may immediately print their documentation of credit. Those who mail or fax back their successfully completed post-test and evaluation form will receive documentation of credit by mail within 6 weeks.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.

Release Date: August 1, 2007; Expiration Date: August 1, 2008

Estimated time to complete: 1 hour

There is no fee associated with this activity.

Lecture Components

The presentation slides, post-test, and evaluation form are available as a click through via the menu at the top of each page of this educational activity.

CME Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the American Academy of CME, Inc and Princeton CME. The American Academy of CME, Inc is accredited by the ACCME to provide continuing medical education for physicians.

The American Academy of CME, Inc designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

To contact the American Academy of CME, Inc please e-mail dbottinick@academycme.org or call 609-921-6622.

CNE Accreditation

The American Academy of CME, Inc is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

The American Academy of CME, Inc designates this activity for 1.0 contact hour.

CPE Accreditation

Princeton CME is accredited by the Accreditation Council for Pharmacy Education as a Provider of continuing pharmacy education (ACPE Provider #452) and complies with the Criteria for Quality and Interpretive Guidelines. This activity is approved for 1 hour credit (0.1 CEU) of continuing pharmacy education (ACPE #452-297-07-022-H01).

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity sponsored or cosponsored by Princeton CME may contact the Assistant Director of Continuing Education in writing. The Assistant Director of Continuing Education will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Director of Continuing Education may be made for a second level of review.

Grant Support

Supported by an educational grant from Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals North America, Inc.

Participating Faculty

Presenters

Brooks D. Cash, MD, FACP, FACG
Chief, Gastroenterology Division and Colon Health Initiative
Associate Professor of Medicine, Uniformed Services University of the Health Sciences
Specialty Leader, Gastroenterology
National Naval Medical Center
Bethesda, Maryland

John R. Horn, PharmD, FCCP
Professor, Department of Pharmacy
Associate Director, University of Washington Medical Center
Department of Pharmacy Services
Seattle, Washington

Independent Clinical Reviewer

Ronnie Fass, MD
Professor of Medicine
University of Arizona
Director, GI Motility Laboratories
University of Arizona Health Sciences Center
Tucson, Arizona

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of the American Academy of CME, Inc and Princeton CME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of the Academy and Princeton CME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Dr. Cash: Speaker—Novartis, Sucampo Pharmaceuticals, Inc., Takeda Pharmaceuticals North America Inc.

Dr. Horn: Advisory board—CV Therapeutics; Speaker—CV Therapeutics, Pfizer, PriCara.

Dr. Fass: Scientific advisory board—GlaxoSmithKline, AstraZeneca, TAP, Wyeth, Pfizer; Scientific consulting—GlaxoSmithKline, Altana, TAP, Ocera Therapeutics; Speaker Honoraria—AstraZeneca, Eisai, Altana, TAP.

Planning Committee Debra Bottinick and Natalie Kirkwood, American Academy of CME, Inc; Randy Robbin and John Savage, Princeton CME; Rosemary Hodgson, William Kormos, and Rob Brosen, Princeton Media Associates have disclosed no relevant financial relationships with any commercial interests.

The American Academy of CME, Inc and Princeton CME, Inc require faculty to inform participants whenever off-label/unapproved uses of drugs or devices are discussed in their presentation.

The faculty has disclosed that the following off-label/unapproved uses of drugs or devices will be discussed: use of the investigative agents linaclotide acetate and renzapride and the use of lubiprostone in the treatment of irritable bowel syndrome with a predominant bowel complaint of constipation.